Published in Biochemistry on June 16, 1998
HIV-1 protease molecular dynamics of a wild-type and of the V82F/I84V mutant: possible contributions to drug resistance and a potential new target site for drugs. Protein Sci (2004) 2.34
Catalytic efficiency and vitality of HIV-1 proteases from African viral subtypes. Proc Natl Acad Sci U S A (2001) 1.64
Computational study of protein specificity: the molecular basis of HIV-1 protease drug resistance. Proc Natl Acad Sci U S A (2001) 1.58
Initial cleavage of the human immunodeficiency virus type 1 GagPol precursor by its activated protease occurs by an intramolecular mechanism. J Virol (2004) 1.52
Lack of synergy for inhibitors targeting a multi-drug-resistant HIV-1 protease. Protein Sci (2002) 1.49
Molecular basis for substrate recognition and drug resistance from 1.1 to 1.6 angstroms resolution crystal structures of HIV-1 protease mutants with substrate analogs. FEBS J (2005) 1.46
Viability of a drug-resistant human immunodeficiency virus type 1 protease variant: structural insights for better antiviral therapy. J Virol (2003) 1.37
Overcoming drug resistance in HIV-1 chemotherapy: the binding thermodynamics of Amprenavir and TMC-126 to wild-type and drug-resistant mutants of the HIV-1 protease. Protein Sci (2002) 1.33
Thermodynamic dissection of the binding energetics of KNI-272, a potent HIV-1 protease inhibitor. Protein Sci (2000) 1.31
Role of invariant Thr80 in human immunodeficiency virus type 1 protease structure, function, and viral infectivity. J Virol (2006) 1.10
Sensitive genetic screen for protease activity based on a cyclic AMP signaling cascade in Escherichia coli. J Bacteriol (2000) 1.07
Atazanavir signature I50L resistance substitution accounts for unique phenotype of increased susceptibility to other protease inhibitors in a variety of human immunodeficiency virus type 1 genetic backbones. Antimicrob Agents Chemother (2005) 0.94
Molecular epidemiology of HIV in a cohort of men having sex with men from Istanbul. Med Microbiol Immunol (2013) 0.93
Systematic mutational analysis of the active-site threonine of HIV-1 proteinase: rethinking the "fireman's grip" hypothesis. Protein Sci (2000) 0.92
X-ray crystal structures of human immunodeficiency virus type 1 protease mutants complexed with atazanavir. J Virol (2007) 0.92
Computational mutation scanning and drug resistance mechanisms of HIV-1 protease inhibitors. J Phys Chem B (2010) 0.91
Genetic selection for dissociative inhibitors of designated protein-protein interactions. Nat Biotechnol (2000) 0.89
Model system for high-throughput screening of novel human immunodeficiency virus protease inhibitors in Escherichia coli. Antimicrob Agents Chemother (2004) 0.87
A cleavage enzyme-cytometric bead array provides biochemical profiling of resistance mutations in HIV-1 Gag and protease. Biochemistry (2011) 0.86
Structure-based phenotyping predicts HIV-1 protease inhibitor resistance. Protein Sci (2003) 0.86
Validating the vitality strategy for fighting drug resistance. Proteins (2012) 0.81
Defective hydrophobic sliding mechanism and active site expansion in HIV-1 protease drug resistant variant Gly48Thr/Leu89Met: mechanisms for the loss of saquinavir binding potency. Biochemistry (2015) 0.79
Identification of novel HIV 1--protease inhibitors: application of ligand and structure based pharmacophore mapping and virtual screening. PLoS One (2012) 0.75
Quantitative structure-activity relationship by CoMFA for cyclic urea and nonpeptide-cyclic cyanoguanidine derivatives on wild type and mutant HIV-1 protease. J Mol Model (2005) 0.75
Rational design of potent, bioavailable, nonpeptide cyclic ureas as HIV protease inhibitors. Science (1994) 3.44
Mutagenesis of protease cleavage sites in the human immunodeficiency virus type 1 gag polyprotein. J Virol (1991) 2.23
Experimental pathogenicity of recent North American isolates of Yersinia enterocolitica. J Infect Dis (1974) 2.19
Molecular cloning of unintegrated and a portion of integrated moloney murine leukemia viral DNA in bacteriophage lambda. J Virol (1980) 2.10
Human chromosome 12 is required for elevated HIV-1 expression in human-hamster hybrid cells. Science (1989) 2.03
Prediction of peptide retention times in high-pressure liquid chromatography on the basis of amino acid composition. Proc Natl Acad Sci U S A (1980) 1.96
p-Benzoyl-L-phenylalanine, a new photoreactive amino acid. Photolabeling of calmodulin with a synthetic calmodulin-binding peptide. J Biol Chem (1986) 1.75
Multiple integration sites for Moloney murine leukemia virus in productively infected mouse fibroblasts. J Virol (1979) 1.73
Rat brain phenolsulfotransferase: partial purification and some properties. Biochim Biophys Acta (1973) 1.64
The regulation of sequential processing of HIV-1 Gag by the viral protease. Adv Exp Med Biol (1998) 1.41
Recognition and characterization of calmodulin-binding sequences in peptides and proteins. Methods Enzymol (1987) 1.39
Inositol bis-, tris-, and tetrakis(phosphate)s: analysis in tissues by HPLC. Proc Natl Acad Sci U S A (1986) 1.38
High-level synthesis of recombinant HIV-1 protease and the recovery of active enzyme from inclusion bodies. Gene (1990) 1.33
Cyclic urea amides: HIV-1 protease inhibitors with low nanomolar potency against both wild type and protease inhibitor resistant mutants of HIV. J Med Chem (1997) 1.27
Coupling of inositol phospholipid metabolism with excitatory amino acid recognition sites in rat hippocampus. J Neurochem (1986) 1.26
Acetylcholine and choline in neuronal tissue measured by HPLC with electrochemical detection. J Neurochem (1983) 1.23
Determinants of the human immunodeficiency virus type 1 p15NC-RNA interaction that affect enhanced cleavage by the viral protease. J Virol (1997) 1.22
Cyclic HIV protease inhibitors: synthesis, conformational analysis, P2/P2' structure-activity relationship, and molecular recognition of cyclic ureas. J Med Chem (1996) 1.20
Virus-secific transcription in 3T3 cells transformed by the ts-a mutant of polyoma virus. J Virol (1977) 1.20
Cleavage of p15 protein in vitro by human immunodeficiency virus type 1 protease is RNA dependent. J Virol (1994) 1.18
Expanded-spectrum nonnucleoside reverse transcriptase inhibitors inhibit clinically relevant mutant variants of human immunodeficiency virus type 1. Antimicrob Agents Chemother (1999) 1.17
Synthesis and evaluation of benzoxazinones as HIV-1 reverse transcriptase inhibitors. Analogs of Efavirenz (SUSTIVA). Bioorg Med Chem Lett (1999) 1.15
Fluorescence properties of calmodulin-binding peptides reflect alpha-helical periodicity. Science (1987) 1.10
Nonsymmetric P2/P2' cyclic urea HIV protease inhibitors. Structure-activity relationship, bioavailability, and resistance profile of monoindazole-substituted P2 analogues. J Med Chem (1998) 1.09
Endogenous type C retroviral sequences of mice are organized in a small number of virus-like classes and have been acquired recently. J Virol (1981) 1.09
Improved cyclic urea inhibitors of the HIV-1 protease: synthesis, potency, resistance profile, human pharmacokinetics and X-ray crystal structure of DMP 450. Chem Biol (1996) 1.06
Synthesis and evaluation of quinoxalinones as HIV-1 reverse transcriptase inhibitors. Bioorg Med Chem Lett (2000) 1.04
Integrated Moloney murine leukemia virus DNA studied by using complementary DNA which does not recognize endogenous related sequences. J Virol (1980) 1.03
Thymosin beta 10, a new analog of thymosin beta 4 in mammalian tissues. Arch Biochem Biophys (1983) 1.02
Photolabeling of calmodulin with basic, amphiphilic alpha-helical peptides containing p-benzoylphenylalanine. J Biol Chem (1989) 1.01
In vitro anti-human immunodeficiency virus (HIV) activity of XM323, a novel HIV protease inhibitor. Antimicrob Agents Chemother (1993) 1.00
Fluorometric estimation of 4-hydroxy-3-methoxyphenylethyleneglycol sulphate in brain. Br J Pharmacol (1972) 0.99
Demonstration of inositol 1,3,4,5-tetrakisphosphate receptor binding. Biochem Biophys Res Commun (1987) 0.99
Isolation, characterization, and purification to homogeneity of a rat brain protein (GABA-modulin). Proc Natl Acad Sci U S A (1982) 0.97
Distribution of thymosin beta 4 in vertebrate classes. Arch Biochem Biophys (1983) 0.95
Enkephalin biosynthesis in adrenal medulla. Modulation of proenkephalin mRNA content of cultured chromaffin cells by 8-bromo-adenosine 3',5'-monophosphate. Mol Pharmacol (1984) 0.94
Proposed structure of two defective viral DNA oligomers produced in 3T3 cells transformed by the ts-a mutant of polyoma virus. J Virol (1976) 0.94
Drug design with a new transition state analog of the hydrated carbonyl: silicon-based inhibitors of the HIV protease. Chem Biol (2001) 0.92
The rate of formation of 3-methoxy-4-hydroxyphenylethyleneglycol sulfate in brain as an estimate of the rate of formation of norepinephrine. J Pharmacol Exp Ther (1973) 0.92
Synthesis and evaluation of analogs of Efavirenz (SUSTIVA) as HIV-1 reverse transcriptase inhibitors. Bioorg Med Chem Lett (1999) 0.92
Construction of infectious molecular clones of HIV-1 containing defined mutations in the protease gene. Biochem Biophys Res Commun (1994) 0.92
Occurrence and localization of brain phenolsulphotransferase. J Neurochem (1974) 0.91
Is cerebrospinal fluid the major avenue for the removal of 5-hydroxyindoleacetic acid from the brain? Neuropharmacology (1973) 0.91
A pharmacokinetic evaluation of HIV protease inhibitors, cyclic ureas, in rats and dogs. Biopharm Drug Dispos (1994) 0.90
Potency and selectivity of inhibition of human immunodeficiency virus protease by a small nonpeptide cyclic urea, DMP 323. Antimicrob Agents Chemother (1994) 0.89
Evidence for a tonic GABAergic control of serotonin neurons in the median raphe nucleus. Brain Res (1981) 0.87
Enkephalin catabolism in vitro and in vivo. Neuropharmacology (1977) 0.87
4,1-Benzoxazepinone analogues of efavirenz (Sustiva) as HIV-1 reverse transcriptase inhibitors. Bioorg Med Chem Lett (2001) 0.87
Compartmentation of mitochondrial creatine phosphokinase. I. Direct demonstration of compartmentation with the use of labeled precursors. J Biol Chem (1982) 0.87
Inhibition of clinically relevant mutant variants of HIV-1 by quinazolinone non-nucleoside reverse transcriptase inhibitors. J Med Chem (2000) 0.87
Compartmentation of mitochondrial creatine phosphokinase. II. The importance of the outer mitochondrial membrane for mitochondrial compartmentation. J Biol Chem (1982) 0.87
Predicted calmodulin-binding sequence in the gamma subunit of phosphorylase b kinase. Proteins (1987) 0.86
Catecholamines: diminished rate of synth- esis in rat brain and heart after thyroxine pretreatment. Life Sci I (1970) 0.84
Human chromosome-dependent and -independent pathways for HIV-2 trans-activation. AIDS Res Hum Retroviruses (1991) 0.84
Evidence for functional hexokinase compartmentation in rat skeletal muscle mitochondria. J Biol Chem (1984) 0.84
Serotonin and gamma-aminobutyric acid turnover after injection into the median raphe of substance P and D-ala-met-enkephalin amide. J Neurochem (1982) 0.82
Nonpeptide cyclic cyanoguanidines as HIV-1 protease inhibitors: synthesis, structure-activity relationships, and X-ray crystal structure studies. J Med Chem (1998) 0.81
Modulation of brain tryptophan hydroxylase activity by brain tryptophan content. J Pharmacol Exp Ther (1977) 0.81
Transcription of isolated mouse liver chromatin. Biochemistry (1976) 0.80
The synthesis of symmetrical and unsymmetrical P1/P1' cyclic ureas as HIV protease inhibitors. Bioorg Med Chem Lett (1998) 0.80
Tryptophan 5-hydroxylase: approximation of half-life and rate of axonal transport. J Neurochem (1972) 0.80
Intimate coupling of creatine phosphokinase and myofibrillar adenosinetriphosphatase. Biochem Biophys Res Commun (1980) 0.80
Efavirenz is a potent nonnucleoside reverse transcriptase inhibitor of HIV type 1 replication in microglia in vitro. AIDS Res Hum Retroviruses (2000) 0.79
Synthesis and evaluation of novel quinolinones as HIV-1 reverse transcriptase inhibitors. Bioorg Med Chem Lett (2001) 0.79
Ornithine as a precursor of neurotransmitter glutamate: effect of canaline on ornithine aminotransferase activity and glutamate content in the septum of rat brain. Brain Res (1985) 0.79
Synthesis and evaluation of efavirenz (Sustiva) analogues as HIV-1 reverse transcriptase inhibitors: replacement of the cyclopropylacetylene side chain. Bioorg Med Chem Lett (2001) 0.79
Unsymmetrical cyclic ureas as HIV-1 protease inhibitors: novel biaryl indazoles as P2/P2' substituents. Bioorg Med Chem Lett (1999) 0.79
Preparation and structure-activity relationship of novel P1/P1'-substituted cyclic urea-based human immunodeficiency virus type-1 protease inhibitors. J Med Chem (1996) 0.78
Blockade of p-chloromethamphetamine induced 5-hydroxytryptamine depletion by chlorimipramine, chlorpheniramine and meperidine. Biochem Pharmacol (1971) 0.78
Is aspartic acid the neurotransmitter of the perforant pathway? Brain Res (1981) 0.78
Simultaneous determination of haloperidol and its reduced metabolite in serum and plasma by isocratic liquid chromatography with electrochemical detection. Clin Chem (1983) 0.78
Reduction of tryptophan hydroxylase activity and 5-hydroxytryptamine concentration in certain rat brain nuclei after p-chloroamphetamine. J Pharmacol Exp Ther (1976) 0.78
Effects of repeated administration of estradiol benzoate on tubero-infundibular GABAergic activity in male rats. J Neurochem (1985) 0.78
The effects of antidepressants on serotonin turnover in discrete regions of rat brain. Naunyn Schmiedebergs Arch Pharmacol (1979) 0.78
Potent cyclic urea HIV protease inhibitors with 3-aminoindazole P2/P2' groups. Bioorg Med Chem Lett (1998) 0.78
Molecular clones of endogenous murine leukemia virus-related DNA sequences from Balb/c mice: characterization of integration sites. Virology (1984) 0.78
Acetylcholine measurement by high-performance liquid chromatography using an enzyme-loaded postcolumn reactor. Anal Biochem (1984) 0.78
Hallucinogenic phenylethylamines: interactions with serotonin turnover and receptors. Eur J Pharmacol (1974) 0.78
Measurement of tryptophan hydroxylase in single brain nuclei by high pressure liquid chromatography. Brain Res (1975) 0.77
Separation of neuropeptides by HPLC. Adv Biochem Psychopharmacol (1980) 0.77
Tryptophan hydroxylase in discrete brain nuclei: comparison of activity in vitro and in vivo. Eur J Pharmacol (1976) 0.77
Application of inexpensive equipment for high pressure liquid chromatography to assays for taurine, gamma-amino butyric acid, and 5-hydroxytryptophan. Anal Chem (1976) 0.77
Thymosin beta 11: a peptide from trout liver homologous to thymosin beta 4. Arch Biochem Biophys (1984) 0.77
Thymosin beta arg10, a major variant of thymosin beta 10 in rabbit tissues. Arch Biochem Biophys (1983) 0.77
Calmodulin binding to alpha 1-purothionin: solution binding and modeling of the complex. Proteins (1992) 0.77
The synthesis and evaluation of cyclic ureas as HIV protease inhibitors: modifications of the P1/P1' residues. Bioorg Med Chem Lett (1998) 0.76
The creatine-creatine phosphate shuttle for energy transport-compartmentation of creatine phosphokinase in muscle. Adv Exp Med Biol (1982) 0.76
Measurement of 5HT turnover rate in discrete nuclei of rat brain. Life Sci (1976) 0.76
Met-enkephalin: rapid separation from brain extracts using high-pressure liquid chromatography, and quantitation by binding assay. Neurochem Res (1978) 0.76